11 assets in Autoimmune Hemolytic Anemia

Therapeutic assets addressing Autoimmune Hemolytic Anemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Autoimmune Hemolytic Anemia	City of Hope Medical Center	P2	B (57)
Nivestim Autoimmune Hemolytic Anemia	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	P2	B (57)
Acalabrutinib Autoimmune Hemolytic Anemia	City of Hope Medical Center	P2	CCC (53)
Ibrutinib Autoimmune Hemolytic Anemia	Gruppo Italiano Malattie EMatologiche dell'Adulto	P2	CCC (53)
Prednisone Autoimmune Hemolytic Anemia	City of Hope Medical Center	P2	CCC (53)
Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy Autoimmune Hemolytic Anemia	Beijing Boren Hospital	P1	CC (43)
Bcma Car T Cells Autoimmune Hemolytic Anemia	Zhejiang University	Early P1	C (39)
gt801 Autoimmune Hemolytic Anemia	Grit Biotechnology	Early P1	NR ()